Eli Lilly's diabetes drug Mounjaro has gained the backing of Britain's healthcare cost-effectiveness watchdog, which said it would be a good option for patients with poorly controlled type 2 diabetes. The National Institute for Health and Care Excellence (NICE) said in draft final guidance that it estimates some 180,000 people could benefit from the new treatment. Investors have sent Lilly's shares surging, betting that an approval will make it a blockbuster drug.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles